SCWorx Corp. resumed trading on The Nasdaq Capital Market on October 7, 2026, following a decision by the Nasdaq Hearings Panel that granted the company's request for reconsideration of a prior delisting. The panel determined that SCWorx had regained compliance with continued listing requirements, subject to a one-year Panel Monitor period. The company highlighted improved financial performance for the first half of 2026, including significant increases in gross profit and reductions in net loss and operating cash used.
The resumption of trading was detailed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on October 5, 2026. This milestone follows the panel's October 2, 2026 ruling, which approved SCWorx's continued listing after the company addressed deficiencies that had led to a delisting decision on September 17, 2026.
Financial data from the company's unaudited condensed consolidated financial statements for the quarter ended June 30, 2026, show revenue of approximately $706,000 in the second quarter of 2026, up from approximately $683,000 in the same period of 2025. Gross profit rose by approximately 83 percent to about $330,000 in the second quarter of 2026, compared to approximately $180,000 in the prior-year period. For the first six months of 2026, gross profit increased by approximately 122 percent to roughly $705,000, while revenue grew to about $1.45 million from $1.40 million in the comparable period.
The company's net loss for the second quarter of 2026 declined to approximately $121,000 from a net loss of approximately $1.9 million in the second quarter of 2025. For the first half of 2026, the net loss was approximately $295,000, down from approximately $2.4 million in the prior-year period. Management attributed this decrease primarily to higher gross profit and the absence of approximately $1.7 million in interest expense and amortization of debt discount related to convertible notes that were outstanding in the first half of 2025 but are no longer current. Operating expenses remained essentially unchanged during this period.
Cash used in operating activities decreased to approximately $258,000 in the first six months of 2026, compared to approximately $1.1 million in the comparable period of 2025. As of June 30, 2026, SCWorx held approximately $1.3 million in cash. In September 2026, the company raised gross proceeds of $938,000 through a private placement of common stock and warrants.
Tim Hannibal, President and Chief Executive Officer of SCWorx, stated that the company is building a more efficient and scalable healthcare technology company by improving its economic fundamentals while investing in its technology and data assets. SCWorx provides healthcare supply chain data management and analytics solutions, utilizing an AI-enabled Data Management Model that combines large language models with its proprietary healthcare data assets and human quality-assurance processes.
During 2026, SCWorx expanded its customer base with new agreements involving major healthcare organizations, including a not-for-profit teaching hospital and a two-year contract with one of Massachusetts' largest integrated delivery networks. The company's strategy focuses on increasing recurring revenue through multi-year customer relationships and expanding the application of its data management capabilities across supply chain, ERP, and interoperability environments.